Literature DB >> 20503691

The blindness, deafness and madness of King George III: psychiatric interactions.

T J Peters1, A Beveridge.   

Abstract

Recent research has thrown considerable doubt on the claim that King George III suffered from variegate porphyria, but indicates that he suffered recurrent attacks of mania as part of his bipolar disorder. George III's last episode of ill health occurred during the final decade of his life (1810-20). This has been diagnosed as chronic mania with an element of dementia. During this period the king was blind and possibly deaf, which may have contributed to his psychiatric condition. His blindness was due to bilateral cataracts; serious consideration was given at the time to surgery, but this was not carried out. The possible contribution of the king's blindness to his illness is discussed with respect to the roles of his medical attendants. It was also claimed that George III showed progressive deafness and this claim has been re-examined. However, the medical reports by the attending physicians and psychiatrists (mad doctors) do not support this claim.

Entities:  

Mesh:

Year:  2010        PMID: 20503691     DOI: 10.4997/jrcpe.2010.116

Source DB:  PubMed          Journal:  J R Coll Physicians Edinb        ISSN: 1478-2715


  4 in total

1.  [Existence, Absence and Power of Madness: A Critical Review of Michel Foucault's Writings on the History and Philosophy of Madness].

Authors:  Burkhart Brückner; Lukas Iwer; Samuel Thoma
Journal:  NTM       Date:  2017-03

2.  Multiple sclerosis or neuromyelitis optica? Re-evaluating an 18th-century illness using 21st-century software.

Authors:  Peter Garrard; Timothy J Peters
Journal:  JRSM Short Rep       Date:  2012-01-12

3.  Madness and Rulers: Events in Coorg and London in 1810, as observed by the Hon. Arthur Cole, the resident at Mysore.

Authors:  Sanjeev Jain; Alok Sarin
Journal:  Indian J Psychiatry       Date:  2015 Apr-Jun       Impact factor: 1.759

4.  The acute mania of King George III: A computational linguistic analysis.

Authors:  Vassiliki Rentoumi; Timothy Peters; Jonathan Conlin; Peter Garrard
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.